Epinephrine Market Is Estimated To Witness High Growth Owing To Rising Cases of Anaphylaxis & Increasing Awareness Regarding Epinephrine Auto-Injectors
Epinephrine Market |
The Global Epinephrine Market is estimated
to be valued at US$ 2,040 million in 2017 and is expected to exhibit a CAGR of
11.0% over the forecast period (2018-2026), as highlighted in a new report
published by Coherent Market Insights.
Market Overview:
Epinephrine, also known as adrenaline, is a hormone and neurotransmitter
produced by the adrenal glands in the body. It is commonly used in the
treatment of anaphylaxis, a severe allergic reaction that can be
life-threatening. Epinephrine auto-injectors are widely prescribed and used by
individuals with a history of severe allergic reactions to be self-administered
in emergency situations. The growing prevalence of anaphylaxis, along with
increasing awareness regarding the importance of epinephrine auto-injectors, is
driving the demand for epinephrine in the market.
Market Dynamics:
The epinephrine market is driven by two major factors:
1. Rising Cases of Anaphylaxis: The prevalence of anaphylaxis is increasing
globally, mainly due to the rising incidence of allergies, particularly food
allergies. According to the Food Allergy Research & Education (FARE), an
estimated 32 million people in the United States have food allergies, and every
three minutes, someone visits the emergency room due to a food-related allergic
reaction. The need for prompt treatment of anaphylaxis through the
administration of epinephrine auto-injectors is fueling the demand for
epinephrine in the market.
2. Increasing Awareness Regarding Epinephrine Auto-Injectors: With growing
awareness among the general population and healthcare professionals about the
potential severity of allergic reactions and the importance of immediate
treatment, there has been a significant increase in the demand for epinephrine
auto-injectors. Various awareness campaigns and initiatives by organizations
such as the World Allergy Organization (WAO) and the American Academy of
Allergy, Asthma & Immunology (AAAAI) are contributing to the market growth.
SWOT Analysis:
Strengths:
1. Life-saving Treatment: Epinephrine auto-injectors provide immediate relief
in anaphylactic reactions, making them a life-saving treatment option.
2. Wide Availability: Epinephrine auto-injectors are widely available and can
be easily obtained with a prescription.
Weaknesses:
1. Short Shelf Life: Epinephrine has a relatively short shelf life, which can
be a challenge for patients who may need to replace their auto-injectors
frequently.
2. Limited Awareness in Developing Regions: The awareness regarding anaphylaxis
and the availability of epinephrine auto-injectors is relatively lower in
developing regions, impacting the market growth potential.
Opportunities:
1. Technological Advancements: Continuous advancements in epinephrine
auto-injector technology, such as the development of smaller and more
user-friendly devices, can expand the market opportunities.
2. Emerging Economies: The increasing prevalence of allergies and growing
disposable incomes in emerging economies present untapped opportunities for
market growth.
Threats:
1. Low Adherence to Epinephrine Usage: Some individuals may fail to adhere to
the recommended use of epinephrine auto-injectors due to fear, lack of
understanding, or discomfort in administering the injection.
2. Stringent Regulatory Requirements: The regulatory requirements for the
approval and marketing of epinephrine auto-injectors can pose challenges for manufacturers.
Key Takeaways:
- The Global
Epinephrine Market Demand is expected to witness high growth,
exhibiting a CAGR of 11.0% over the forecast period, due to increasing cases of
anaphylaxis and rising awareness regarding the importance of epinephrine auto-injectors.
- North America is expected to dominate the market, driven by the high
prevalence of allergies and the availability of advanced healthcare
infrastructure.
- Key players operating in the global Epinephrine market include Mylan N.V.,
Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Impax Laboratories, Inc.,
Kaleo, Inc., Adamis Pharmaceuticals Corporation, Bausch Health Companies, and
ALK-Abello A/S.
In conclusion, the global Epinephrine market is witnessing significant growth
due to the increasing cases of anaphylaxis and the growing awareness regarding
the importance of epinephrine auto-injectors. However, challenges such as low
adherence and stringent regulatory requirements need to be addressed to
capitalize on the market's full potential.
Comments
Post a Comment